Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer

The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence

(2018) Sara Jansson et al.   BREAST CANCER RESEARCH AND TREATMENT

Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor

(2018) Alexander D. Barrow et al.   CELL

Receptor Tyrosine Kinase Ubiquitination and De-Ubiquitination in Signal Transduction and Receptor Trafficking

(2018) William Critchley et al.   Cells

CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer

(2018) Murugan Kalimutho et al.   EMBO Molecular Medicine

Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages

(2017) Francesca Bellora et al.   JOURNAL OF IMMUNOLOGY

Cancer stem cells revisited

(2017) Eduard Batlle et al.   NATURE MEDICINE

The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells

(2017) Alison M. Anderson et al.   Scientific Reports

Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis

(2016) D. Mittal et al.   CANCER RESEARCH

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

(2016) Peter J.R. Ebert et al.   IMMUNITY

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer

(2016) Peter B. Alexander et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach

(2016) Sriganesh Srihari et al.   Molecular BioSystems

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence

(2016) Justin M. Balko et al.   Science Translational Medicine

The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma

(2016) Christine M. Heske et al.   Translational Oncology

Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models

(2016) Alessia Bottos et al.   Nature Communications

Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer

(2015) Sung Yeon Park et al.   BREAST CANCER RESEARCH AND TREATMENT

AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer

(2015) Aya Kobayashi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth

(2015) G. Gritsina et al.   MOLECULAR CANCER THERAPEUTICS

MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms

(2015) Pui-Kei Wu et al.   SEMINARS IN ONCOLOGY

Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease

(2015) Murugan Kalimutho et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer

(2015) Fares Al-Ejeh et al.   Oncotarget

Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

(2014) H. R. Ali et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

PDGFR  and   Play Critical Roles in Mediating Foxq1-Driven Breast Cancer Stemness and Chemoresistance

(2014) F. Meng et al.   CANCER RESEARCH

PDGF/PDGFR Signaling and Targeting in Cancer Growth and Progression: Focus on Tumor Microenvironment and Cancer-associated Fibroblasts

(2014) Chrisostomi Gialeli et al.   CURRENT PHARMACEUTICAL DESIGN

Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm

(2014) Guangyao Kong et al.   JOURNAL OF CLINICAL INVESTIGATION

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer

(2014) Sandra Van Schaeybroeck et al.   Cell Reports

Targeting the PDGF signaling pathway in tumor treatment

(2013) Carl-Henrik Heldin   Cell Communication and Signaling

Pathway-based personalized analysis of cancer

(2013) Y. Drier et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients

(2013) David Akhavan et al.   Cancer Discovery

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

(2012) Adrian Britschgi et al.   CANCER CELL

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

(2012) James S. Duncan et al.   CELL

Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy

(2012) J. S. Logue et al.   GENES & DEVELOPMENT

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

(2012) Justin M Balko et al.   NATURE MEDICINE

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

(2012) Wanjuan Yang et al.   NUCLEIC ACIDS RESEARCH

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21waf1/cip1-independent pathway in human colorectal cancer cells

(2011) Murugan Kalimutho et al.   ACTA PHARMACOLOGICA SINICA

The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors

(2011) Lauren L.C. Marotta et al.   JOURNAL OF CLINICAL INVESTIGATION

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

(2010) Alfonso Sánchez-Muñoz et al.   BMC CANCER

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

(2010) J. Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer

(2009) Janna Paulsson et al.   AMERICAN JOURNAL OF PATHOLOGY

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

(2009) Balazs Györffy et al.   BREAST CANCER RESEARCH AND TREATMENT

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

(2009) L. M. Ellis et al.   CLINICAL CANCER RESEARCH

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Reciprocal Effects of STAT5 and STAT3 in Breast Cancer

(2009) S. R. Walker et al.   MOLECULAR CANCER RESEARCH

Role of platelet-derived growth factors in physiology and medicine

(2008) J. Andrae et al.   GENES & DEVELOPMENT